Medicure Inc.
Medicure Inc. is a pharmaceutical company dedicated to the research, development, and commercialization of innovative treatments for cardiovascular health. As an integrated firm, Medicure not only engages in drug development but also focuses on the entire lifecycle of pharmaceuticals from conception to market. This includes regulatory processes and marketing efforts, ensuring a comprehensive approach to bringing new medications to patients. Medicure’s flagship product has been instrumental in the treatment of acute heart conditions, showcasing the company's ability to impact the healthcare sector significantly. Operating primarily in the North American market, Medicure has strategically positioned itself to contribute to both the scientific community and healthcare professionals. The company's ongoing commitment to advancing cardiovascular treatment options underscores its role as a key player in the pharmaceutical industry, offering vital products that enhance patient outcomes and support healthcare innovation.
$3.03
+$0.09 (+3.06%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-23.87% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 31.7%, still solid. Margins contracted 11.4pp, which offsets some of the top-line progress.
Free cash flow declined 188% versus the prior year, cash generation momentum has weakened. ROIC dropped from -10.27% to -30.70%, capital efficiency is deteriorating.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$32M
▲ +31.7% YoY
Net Income (TTM)
-C$7M
▼ -583.1% YoY
Op. Margin
-22.62%
▼ -11.4pp YoY
ROIC
-30.70%
▼ -20.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$2M
▼ -187.8% YoY
Op. Cash Flow (TTM)
-C$2M
▼ -137.7% YoY
Net Debt
-C$3M
Net Cash Position
Cash & Equiv.
C$4M
3Y CAGR: +7.8%
Continue Research
Is Medicure (MCUJF) overvalued?
Medicure (MCUJF)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Medicure scores 31/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Medicure a high-quality business?+
Medicure scores 31 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -22.6% operating margin and a -30.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Medicure a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh MCUJF's valuation and scores 31/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Drug Manufacturers - Specialty & Generic
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.